Glucotrack to begin research & development of novel continuous glucose monitoring system

Rutherford, nj, oct. 10, 2022 (globe newswire) -- glucotrack, inc. (nasdaq: gctk) (“glucotrack” or the “company”), a non-invasive device and digital health platform for measuring glucose levels in people with type 2 diabetes and prediabetes, announced today it is expanding its product pipeline with the commencement of a new r&d program for a long-term continuous glucose monitor.
GCTK Ratings Summary
GCTK Quant Ranking